This invention relates to ion exchange membranes, especially anion exchange membranes (AEMs), their preparation processes and their use.

Ion exchange membranes are used in electrodialysis, electrolysis, production of acids and bases and a number of other processes. Typically the transport of ions through the membranes occurs under the influence of a driving force such as an electrical potential gradient.

Some ion exchange membranes comprise a porous support, which provides mechanical strength. Such membranes are often called “composite membranes” due to the presence of both an ionically charged polymer which discriminates between oppositely charged ions and the porous support which provides mechanical strength.

For generation of acids and bases generally BPMs are used, e.g. in a process called bipolar electrodialysis (BPED). A BPM has both a cationic layer or anion exchange layer (AEL) and an anionic layer or cation exchange layer (CEL) and thus has both a negatively charged layer and a positively charged layer.

In the BPED process acid and base are generated at the interface of a BPM by means of a water dissociation reaction (WDR). The IT and OH’ ions generated travel across the corresponding ion exchange layers towards the cathode and the anode respectively. The BPED process is performed in a bipolar electrodialysis stack comprising additional to bipolar membranes monopolar anion exchange and monopolar cation exchange membranes. In the bipolar electrodialysis stack, the monopolar cation and anion exchange membranes take care of selectively separating the salt ions of the feed stream by their charge. The salt anion will then combine with the H+ formed by the WDR to form an acid and the salt cation will combine with the OH- to form a base. For example, if NaCI is used in the feed stream, the monopolar membranes will separate Na ⁺ from Cl’ whereby NaOH and HCI are formed.

For generation of acids and bases in high concentrations it is important that the monopolar membranes have a very high pH stability and high durability (high pH stability and durability increase the lifetime of the membranes). Also desired is a high efficiency of the process for generating acids and bases. This requires the membranes to have a very high permselectivity to prevent H ⁺ and OH’ ions to reach the wrong channel causing recombination and hence product loss. Especially for anion exchange membranes it is difficult to obtain a high proton blocking performance at high concentrations due to the small size of protons.

It is an aim of the present invention to provide anion exchange membranes which are mechanically strong, having a high stability at very low pH values and a high permselectivity at high acid concentrations.

According to a first aspect of the present invention there is provided an anion exchange membrane obtainable by curing a curable composition comprising:

(a) a monomer (a) of Formula (I) AR ¹ - (CH ₂ )n - N ⁺ (R ^a R ^b ) - (CH ₂ )n - AR ² , X" Formula (I) wherein: each n independently has a value of 1 or 2;

(i) R ^a and R ^b are each independently an optionally substituted Ci-3-alkyl group or an optionally substituted C ₂ -3-alkenyl group; or

(ii) R ^a and R ^b , together with the positively charged nitrogen atom to which they are attached, form an optionally substituted 5- or 6-membered ring; or

(iii) one of R ^a and R ^b is an optionally substituted Ci-3-alkyl group or an optionally substituted C ₂ -3-alkenyl group and the other of R ^a and R ^b , together with the group of formula AR ¹ - (CH ₂ ) _n - N ⁺ , forms an optionally substituted 5- or 6-membered ring; or

(iv) R ^a , together with the group of formula AR ¹ - (CH ₂ ) _n - N ⁺ , forms an optionally substituted 5- or 6-membered ring, and R ^b , together with the group of formula N ⁺ - (CH ₂ ) _n - AR ² , forms an optionally substituted 5- or 6-membered ring;

X’ is an anion; and

AR ¹ and AR ² are each independently comprise aromatic groups; wherein:

(I) at least one of AR ¹ and AR ² comprises a curable ethylenically unsaturated group;

(II) the monomer (a) of Formula (I) comprises at least two curable ethylenically unsaturated groups; and

(III) the molar fraction of component (a) in relation to all curable components of the curable composition is at least 0.90.

In this document (including its claims), the verb "comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually mean "at least one".

Preferably monomer (a) comprises at least two curable ethylenically unsaturated groups, more preferably two and only two curable ethylenically unsaturated groups. Preferably the curable ethylenically unsaturated present in monomer (a) are present in AR ¹ and/or AR ² . In a preferred embodiment AR ¹ and AR ² each comprise one and only one curable ethylenically unsaturated group and monomer (a) has a total of two curable ethylenically unsaturated groups.

The curable ethylenically unsaturated groups are capable of reacting with other curable ethylenically unsaturated groups to form covalent bonds therewith, e.g. when heated and/or irradiated with light (e.g. ultraviolet light) or an electron beam. Preferred curable ethylenically unsaturated groups are vinyl groups and allyl groups, most preferably vinyl groups. The vinyl groups (CH2=CH-) are non-acrylic, i.e. the vinyl groups are not attached to (C=O)O-groups or (C=O)NH-groups.

The positively charged nitrogen atom (N ⁺ ) shown in Formula (I) is non-aromatic, i.e. is not part of an aromatic heterocyclic ring.

Preferably the anion X’ does not react with the other components of the curable composition, i.e. X’ is inert. Preferred anions represented by X’ include hydroxide, fluoride, chloride, bromide, iodide, nitrate, thiocyanate, hexafluoroborate, methanesulfonate, trifluoromethanesulfonate, formate and acetate. Most preferably X’ is a chloride anion because this can provide monomers of Formula (I) with good solubility without dramatically increasing the molecular weight of monomer (a) of Formula (I).

Preferably each n independently has a value of 1. In a particularly preferred embodiment both n have a value of 1 .

In one embodiment R ^a and R ^b are each independently selected from optionally substituted Ci-3-alkyl groups (e.g. methyl, ethyl, propyl or isopropyl) and optionally substituted C2-3-alkenyl groups (e.g. -CH=CH2or -CFhCF CFh).

In another embodiment R ^a and R ^b , together with the positively charged nitrogen atom to which they are attached, form an optionally substituted 5- or 6-membered ring, for example an optionally substituted pyrrolidinium, pyrrolinium, imidazolinium piperidinium or morpholinium ring.

In another embodiment, one of R ^a and R ^b is an optionally substituted Ci-3-alkyl group or an optionally substituted C2-3-alkenyl group and the other of R ^a and R ^b , together with the group of formula AR ¹ - (CH2)n - N ⁺ (wherein AR ¹ and n are as hereinbefore defined), forms an optionally substituted 5- or 6-membered ring, for example an optionally substituted pyrrolidinium, pyrrolinium, piperidinium or morpholinium ring, in each case having an aromatic ring (e.g. a benzene ring) fused thereon (preferably with two or more, preferably one, curable ethylenically unsaturated groups attached to the benzene ring).

In another embodiment R ^a , together with the group of formula AR ¹ - (CH2)n - N ⁺ (wherein AR ¹ and n are as hereinbefore defined), forms an optionally substituted 5- or 6-membered ring and R ^b , together with the group of formula N ⁺ - (CH2)n - AR ² (wherein AR ² and n are as hereinbefore defined) forms an optionally substituted 5- or 6- membered ring.

The preferred optionally substituted 5- or 6-membered rings are as hereinbefore defined (one example is a 6-azoniaspiro[5.5]undecylene ring).

Preferred optional substituents are curable ethylenically unsaturated groups (as hereinbefore described and preferred).

Preferably AR ¹ and AR ² each independently comprise a phenyl orstyrenyl group. More preferably both AR ¹ and AR ² are styrenyl groups.

In a preferred embodiment monomer (a) is of Formula (II):

Formula (II) wherein R ^a , R ^b and X’ are as hereinbefore defined. Component (a) optionally comprises one or more than one monomer (a) of

Formula (I) (more preferably Formula (II)), for example a mixture of isomers wherein curable unsaturated groups present in AR ¹ and/or AR ² are in different positions (e.g. ortho, meta and/or para position).

Examples of monomers which may be used as monomer (a) include the compounds AXL-1 to AX-11 shown below:

The curable composition preferably comprises 50 to 90wt% of component (a), more preferably 65 to 85wt%, especially 69 to 83wt%.

In one embodiment the anion exchange membrane according to the first aspect of the present invention comprises at least 1 ppm of monomer (a) (typically as a result of incomplete curing when the membrane is formed), preferably at least 10 ppm, especially at least 100 ppm. Preferably the anion exchange membrane comprises less than 20,000 ppm of monomer (a), more preferably less than 10,000 ppm.

The curable composition optionally further comprises a monomer comprising a cationically charged group and one and only one curable ethylenically unsaturated group as component (b). Preferably the curable composition is free from component (b) or the composition comprises a small amount of component (b), e.g. the curable composition preferably comprises 0 to 10wt% of component (b), more preferably 0 to 7wt% of component (b).

In monomer (b) the cationically charged group is preferably a quaternary ammonium group. The one and only curable ethylenically unsaturated group present in monomer (b) is preferably a vinyl or allyl group, more preferably a vinyl group.

Component (b) may comprise one or more than one monomer (b) comprising a cationically charged group and one and only one curable ethylenically unsaturated group.

In one embodiment component (b) is of Formula (SM) wherein R ¹ , R ² and R ³ each independently represents an alkyl group or an aryl group, or 2 or 3 of R ¹ , R ² and R ³ together with the positively charged nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; n3 represents an integer of 1 to 3; and X3 ⁰ represents an anion, preferably chloride, bromide, iodide or hydroxide. Examples of component (b) of Formula (SM) include the following: compounds.

The above components may be prepared as described in, for example, US2016177006.

The curable composition optionally further comprises a radical initiator as component (c). Preferred radical initiators include thermal initiators, photoinitiators and combinations thereof.

The curable composition preferably comprises 0 to 10 wt% of radical initiator, more preferably 0 to 3wt%. When the curable composition is to be cured using UV light, visible light or thermally the curable composition preferably 0.001 to 2wt%, especially 0.005 to 1 ,5wt%, of radical initiator.

Examples of suitable thermal initiators which may be used as component (c) include 2,2’-azobis(2-methylpropionitrile) (AIBN), 4,4’-azobis(4-cyanovaleric acid), 2,2’- azobis(2,4-dimethyl valeronitrile), 2,2’-azobis(2-methylbutyronitrile), 1 ,1 ’- azobis(cyclohexane-1 -carbonitrile), 2,2’-azobis(4-methoxy-2,4-dimethyl valeronitrile), dimethyl 2,2’-azobis(2-methylpropionate), 2,2’-azobis[N-(2-propenyl)-2- methylpropionamide, 1-[(1-cyano-1-methylethyl)azo]formamide, 2,2'-azobis(N-butyl-2- methylpropionamide), 2,2'-Azobis(N-cyclohexyl-2-methylpropionamide), 2,2'-Azobis(2- methylpropionamidine) dihydrochloride, 2,2'-azobis[2-(2-imidazolin-2- yl)propane]dihydrochloride, 2,2'-azobis[2-(2-imidazolin-2-yl)propane]disulfate dihydrate, 2,2‘-azobis[N-(2-carboxyethyl)-2-methylpropionamidine] hydrate, 2,2'- azobis{2-[1 -(2-hydroxyethyl)-2-imidazolin-2-yl]propane} dihydrochloride, 2,2'-azobis[2- (2-imidazolin-2-yl)propane], 2,2'-azobis(1 -imino- 1 -pyrrolidino-2-ethylpropane) dihydrochloride, 2,2'-azobis{2-methyl-N-[1 , 1 -bis(hydroxymethyl)-2- hydroxyethl]propionamide} and 2,2'-azobis[2-methyl-N-(2-hydroxyethyl) propionamide].

Examples of suitable photoinitiators which may be included in the curable composition as component (c) include aromatic ketones, acylphosphine compounds, aromatic onium salt compounds, organic peroxides, thio compounds, hexa arylbiimidazole compounds, ketoxime ester compounds, borate compounds, azinium compounds, metallocene compounds, active ester compounds, compounds having a carbon halogen bond, and alkyl amine compounds. Preferred examples of the aromatic ketones, the acylphosphine oxide compound, and the thio-compound include compounds having a benzophenone skeleton or a thioxanthone skeleton described in "RADIATION CURING IN POLYMER SCIENCE AND TECHNOLOGY", pp.77-117 (1993). More preferred examples thereof include an alpha-thiobenzophenone compound described in JP1972-6416B (JP-S47-6416B), a benzoin ether compound described in JP1972-3981 B (JP-S47-3981 B), an alpha-substituted benzoin compound described in JP1972-22326B (JP-S47-22326B), a benzoin derivative described in JP1972-23664B (JP-S47-23664B), an aroylphosphonic acid ester described in JP1982- 30704A (JP-S57-30704A), dialkoxybenzophenone described in JP1985-26483B (JP- S60-26483B), benzoin ethers described in JP1985-26403B (JP-S60-26403B) and JP1987-81345A (JPS62-81345A), alpha-amino benzophenones described in JP1989- 34242B (JP H01-34242B), U.S. Pat. No. 4,318, 791 A, and EP0284561A1 , p- di(dimethylaminobenzoyl) benzene described in JP1990-211452A (JP-H02- 211452A), a thio substituted aromatic ketone described in JP1986-194062A (JPS61-194062A), an acylphosphine sulfide described in JP1990-9597B (JP-H02- 9597B), an acylphosphine described in JP1990-9596B (JP-H02-9596B), thioxanthones described in JP1988- 61950B (JP-S63-61950B), and coumarins described in JP1984-42864B (JP-S59- 42864B). In addition, the photoinitiators described in JP2008-105379A and JP2009- 114290A are also preferable. In addition, photoinitiators described in pp. 65 to 148 of "Ultraviolet Curing System" written by Kato Kiyomi (published by Research Center Co., Ltd., 1989) may be used.

Especially preferred photoinitiators include Norrish Type II photoinitiators having an absorption maximum at a wavelength longer than 380nm, when measured in one or more of the following solvents at a temperature of 23°C: water, ethanol and toluene. Examples include a xanthene, flavin, curcumin, porphyrin, anthraquinone, phenoxazine, camphorquinone, phenazine, acridine, phenothiazine, xanthone, thioxanthone, thioxanthene, acridone, flavone, coumarin, fluorenone, quinoline, quinolone, naphtaquinone, quinolinone, arylmethane, azo, benzophenone, carotenoid, cyanine, phtalocyanine, dipyrrin, squarine, stilbene, styryl, triazine or anthocyanin-derived photoinitiator.

Optionally the curable composition further comprises a monomer free from cationically charged groups, preferably comprising at least two curable ethylenically unsaturated groups as component (d).

Preferably the curable composition comprises 0 to 5wt% of component (d). More preferably the curable composition is free from component (d).

The curable composition preferably further comprises a solvent as component (e). The solvent is preferably an inert solvent. Inert solvents do not react with any of the other components of the curable composition. In a preferred embodiment component (e) comprises water and optionally an organic solvent, especially where some or all of the organic solvent is water miscible. The water is useful for dissolving components (a) and (b) and possibly also component (c) and the organic solvent is useful for dissolving any organic components present in the curable composition.

Component (e) is useful for reducing the viscosity and/or surface tension of the curable composition. In a preferred embodiment, the curable composition comprises 10 to 40wt%, especially 20 to 30 wt%, of component (e).

Examples of inert solvents which may be used as or in component (e) include water, alcohol-based solvents, ether-based solvents, amide-based solvents, ketone- based solvents, sulphoxide-based solvents, sulphone-based solvents, nitrile-based solvents and organic phosphorus-based solvents. Examples of alcohol-based solvents which may be used as or in component (e) (especially in combination with water) include methanol, ethanol, isopropanol, n-propanol, n-butanol, ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol and mixtures comprising two or more thereof. In addition, preferred inert, organic solvents which may be used in component (e) include dimethyl sulphoxide, dimethyl imidazolidinone, sulpholane, N- methylpyrrolidone, dimethyl formamide, acetonitrile, acetone, 1 ,4-dioxane, 1 ,3- dioxolane, tetramethyl urea, hexamethyl phosphoramide, hexamethyl phosphorotriamide, pyridine, propionitrile, butanone, cyclohexanone, tetrahydrofuran, tetrahydropyran, 2-methyltetrahydrofuran, ethylene glycol diacetate, cyclopentylmethylether, methylethylketone, ethyl acetate, y-butyrolactone and mixtures comprising two or more thereof.

The molar fraction of component (a) in relation to all curable compounds present in the curable composition is preferably at least 0.91 , more preferably at least 0.95. A high ratio of component (a) in relation to all curable compounds present in the curable composition is preferred to obtain a membrane having a high crosslink density and hence a high permselectivity. The molar fraction of component (a) in relation to all curable compounds present in the curable composition is preferably up to 1 .0.

The molar fraction of component (a) in relation to all curable compounds present in the curable composition may be calculated by dividing the molar amount of component (a) by the sum of the molar amounts of all curable compounds present in the curable composition. Alternatively, the molar fraction may be determined by measuring the extractables from the anion exchange membrane, e.g. as described on page 19 of WO2022162083.

Preferably the ion exchange capacity (I EC) of the anion exchange membrane according to the present invention is at least 1.1 meq/g dry membrane, more preferably at least 1.2 meq/g dry membrane when measured by the method described below. Such lECs can provide anion exchange membranes having low electrical resistance.

Preferably the I EC of the anion exchange membrane according to the present invention is below 1 .65 meq/g dry membrane when measured by the method described below. Such lECs can provide anion exchange membranes which do not swell too much and therefore retain good permselectivity in use.

The anion exchange membrane of the present invention preferably further comprises a porous support.

As examples of porous supports which may be used there may be mentioned woven and non-woven synthetic fabrics and extruded films. Examples include wetlaid and drylaid non-woven material, spunbond and meltblown fabrics and nanofiber webs made from, e.g. polyethylene, polypropylene, polyacrylonitrile, polyvinyl chloride, polyphenylenesulfide, polyester, polyamide, polyaryletherketones such as polyether ether ketone and copolymers thereof. Porous supports may also be porous membranes, e.g. polysulphone, polyethersulphone, polyphenylenesulphone, polyphenylenesulfide, polyimide, polyethermide, polyamide, polyamideimide, polyacrylonitrile, polycarbonate, polyacrylate, cellulose acetate, polypropylene, poly(4- methyl 1 -pentene), polyinylidene fluoride, polytetrafluoroethylene, polyhexafluoropropylene and polychlorotrifluoroethylene membranes and derivatives thereof.

The porous support preferably has an average thickness of between 10 and 800pm, more preferably between 15 and 300pm, especially between 20 and 150pm, more especially between 30 and 130pm, e.g. around 60pm or around 100pm.

Preferably the porous support has a porosity of between 30 and 95%, more preferably of 60 to 75%, wherein (in the final membrane) the pores are filled with an anion exchange polymer derived from curing the composition, i.e. the membrane preferably comprises 25 to 40vol% of porous (non-charged) support material and 75 to 60vol% of anion exchange polymer material (i.e. cured composition according to a first aspect of the present invention). The porosity of the support, prior to making the membrane, may be determined by a porometer, e.g. a Porolux™ 1000 from IB-FT GmbH, Germany.

The porous support, when present, may be treated to modify its surface energy, e.g. to values above 45 mN/m, preferably above 55mN/m. Suitable treatments include corona discharge treatment, plasma glow discharge treatment, flame treatment, ultraviolet light irradiation treatment, chemical treatment or the like, e.g. for the purpose of improving the wettability of and the adhesiveness to the porous support to the anion exchange membrane.

Commercially available porous supports are available from a number of sources, e.g. from Freudenberg Filtration Technologies (Novatexx materials), Lydall Performance Materials, Celgard LLC, APorous Inc., SWM (Conwed Plastics, DelStar Technologies), Teijin, Hirose, Mitsubishi Paper Mills Ltd and Sefar AG.

Preferably the porous support is a porous polymeric support. Preferably the porous support is a woven or non-woven synthetic fabric or an extruded film without covalently bound ionic groups. Preferably the anion exchange membrane of the present invention has an average thickness of between 15pm and 600pm, more preferably of between 50pm and 450pm and especially between 60 and 240pm.

According to a second aspect of the present invention there is provided a process for preparing an anion exchange membrane comprising curing a curable composition as defined (and preferred) in relation to the first aspect of the present invention.

The process according to the second aspect of the present invention preferably comprises the steps of: i. providing a porous support; ii. impregnating the porous support with the curable composition; and iii. curing the curable composition; wherein the curable composition is as defined above.

The curable composition may be cured by any suitable process, including thermal curing, photocuring, electron beam (EB) irradiation, gamma irradiation, and combinations of the foregoing.

Preferably the process according to the second aspect of the present invention comprises a first curing step and a second curing step (dual curing). Dual curing is preferred since it increases the crosslink density of the resultant anion exchange membrane which in turn improves permselectivity.

In a preferred embodiment of the process according to the second aspect of the present invention the curable composition is cured first by photocuring, e.g. by irradiating the curable composition with ultraviolet (UV) or visible light, or by gamma or electron beam radiation, and thereby causing curable components present in the curable composition to polymerise, and then applying a second curing step. The second curing step preferably comprises thermal curing, gamma irradiation or EB irradiation of the product of the first curing step whereby the second curing step preferably applies a different curing technique to the first curing step. When gamma or electron beam irradiation is used in the first curing step preferably a dose of 60 to 200 kGy, more preferably a dose of 80 to 150 kGy is applied to the curable composition.

In one embodiment the process according to the second aspect of the present invention comprises curing the curable composition in a first curing step to form the anion exchange membrane, winding the anion exchange membrane onto a core (optionally together with an inert polymer foil) and then performing the second curing step on the wound product of the first curing step.

In a preferred embodiment the first and second curing steps are respectively selected from (i) UV curing (first curing step) then thermal curing (second curing step); (ii) UV curing then electron beam curing; and (iii) electron beam curing then thermal curing.

Component (c) may comprise just one radical initiator or more than one radical initiator, e.g. a mixture of several photoinitiators (e.g. for single curing) or a mixture of photoinitiators and thermal initiators (e.g. for dual curing). In one embodiment the second curing step is performed using gamma or electron beam (EB) irradiation. For the second curing step by gamma or EB irradiation preferably a dose of 60 to 200 kGy is applied to the product of the first curing step, more preferably a dose of 80 to 150 kGy is applied.

For the optional second curing step, thermal curing is preferred. The thermal curing is preferably performed at a temperature between 50 and 100°C, more preferably between 60 and 90°C. The thermal curing is preferably performed for a period between 2 and 72 hours, e.g. around 3 hours for a sheet, between 8 and 16 hours, e.g. about 10 hours for a small roll and between 24 and 72 hours for a large roll. Optionally after the first curing step a polymer foil is applied to the product of the first curing step before winding it onto a spool (this reduces oxygen inhibition, drying out and/or sticking of the product of the first curing step to itself).

In a preferred process according to the second aspect of the present invention, the curable composition is applied continuously to a moving (preferably porous) support, preferably by means of a manufacturing unit comprising a curable composition application station, one or more irradiation source(s) for curing the curable composition, a membrane collecting station and a means for moving the support from the curable composition application station to the irradiation source(s) and to the membrane collecting station.

The curable composition application station may be located at an upstream position relative to the irradiation source(s) and the irradiation source(s) is/are located at an upstream position relative to the membrane collecting station.

Examples of suitable coating techniques for applying the curable composition to a support include slot die coating, slide coating, air knife coating, roller coating, screenprinting, and dipping. Depending on the used technique and the desired end specifications, it might be desirable to remove excess coating from the substrate by, for example, roll-to-roll squeeze, roll-to-blade or blade-to-roll squeeze, blade-to-blade squeeze or removal using coating bars. Curing by light is preferably done for the first curing step, preferably at a wavelength between 300 nm and 800 nm using a dose between 40 and 20000 mJ/cm ² . In some cases additional drying might be needed for which temperatures between 40°C and 200°C could be employed. When gamma or EB curing is used irradiation may take place under low oxygen conditions, e.g. below 200 ppm oxygen.

According to a third aspect of the present invention there is provided use of (a method for using) the anion exchange membrane according to the first aspect of the present invention for use in electromembrane processes, for example for the treatment of polar liquids (e.g. desalination), for the production the acids and bases or for the generation or storage of electricity.

According to a fourth aspect of the present invention there is provided an electrodialysis or reverse electrodialysis device, a bipolar electrodialysis device, an electrodeionization module, a flow through capacitor, a diffusion dialysis apparatus, a membrane distillation module, an electrolyser, a redox flow battery, an acid-base flow battery or a fuel cell, comprising one or more anion exchange membranes according to the first aspect of the present invention.

The invention will now be illustrated by the following, non-limiting examples in which all parts and percentages are by weight unless specified otherwise. pH stability pH stability of the anion exchange membranes was tested by immersing a sample of the membrane under test in 4M of HCI at 80°C for at least 1 month. After this treatment, the permselectivity (PS) of the membrane was measured and compared to its PS before the immersion. The pH stability of a membrane was deemed to be “OK” if, after the immersion, the PS was at least 80% the original PS; if lower than 80% of the original PS the pH stability was deemed to be not good (“NG”).

Permselectivity (PS)

The permselectivity (PS) (%) (i.e. the selectivity of the anion exchange membranes to the passage of ions of opposite charge) was measured as follows:

The anion exchange membrane to be tested was placed in a two-compartment system. One compartment was filled with a 0.05M solution of HCI and the other with a 4M solution of HCI with the membrane under test separating the two compartments. Settings:

• the capillaries as well as the Ag/AgCI reference electrodes (Metrohm type 6.0750.100) contained 3M KCI;

• the effective membrane area was 9.62 cm ² ;

• the distance between the capillaries was ca 15 mm;

• the measuring temperature was 21 .0 ±0.2 °C;

• a Cole Parmer Masterflex console drive (77521-47) with easy load II model 77200-62 gear pumps was used for the two compartments;

• Porter Instrument flowmeters (type 150AV-B250-4RVS) and Cole Parmer flowmeters (type G-30217-90) were used to control the flow constant at 500 ml/min;

• The anion exchange membrane samples were equilibrated for 1 hr in a 0.25M HCI solution prior to measurement. The voltage was read from a regular VOM (multitester) after 20 minutes.

The PS was calculated from the voltage reading using the Nernst equation. Preferably the PS for HCI was at least 50%.

Ion exchange capacity (I EC)

Prior to measurement, the membranes are brought in the chloride form by immersing the samples in 2 M NaCI solution for 1 hour. The 2 M NaCI solution was refreshed once and the samples were equilibrated for another 24 hours. Subsequently, the membrane samples were rinsed with Milli-Q® water, immersed for 1 hour in fresh Milli-Q® water and rinsed once more with Milli-Q® water.

From the membrane samples with chloride as counter ion 2.0 cm diameter samples were punched out (12.57 cm ² ), dried for 24 hours at 40°C and weighed. Then the samples were placed in 75 ml of milli-Q® water for 24 hours, to remove all none- counter ions, followed by rinsing with Milli-Q® water, soaking each sample in 10.00 ml of a 0.1 M AgNOs solution, and shaking the solutions with the samples for 24 hours. During the shaking Cl -ions were fully exchanged by NOs’ ions as the Ag ⁺ -ions removed the CI’-ions by precipitation of AgCI salt. Subsequently, the samples were taken out of the AgNOs solutions and rinsed with small portions of Milli-Q® water. The rinsing water of each sample and the corresponding AgNOs solution remaining after shaking the membrane sample were combined and titrated with a calibrated 0.1 M KBr solution, and the results were compared with the titration of a blank solution of 10.00 ml of 0.1 M AgNOs which had not contained a membrane sample. The difference between titration results of the blank solution and the test solution of each sample was correlated to the ion exchange capacity of the corresponding membranes using Equation (I):

I EC (meq/g dry membrane) = (Y-X)*0.1/W Equation (I) wherein

Y is the amount of 0.1 M KBr (in ml) used in the titration of the blank AgNOs solution;

X is the amount of 0.1 M KBr (in ml) used in the titration of the AgNOs solution in which the membrane sample had been soaked combined with the Milli-Q® water used for rinsing the membrane sample after soaking in the AgNOs solution; and

W is the dry weight of the membrane (in gram).

Electrical resistance (ER)

ER (ohm. cm ² ) of the anion exchange membranes prepared in the Examples was measured by the method described by Dlugolecki et aL, J. of Membrane Science, 319 (2008) on page 217-218 with the following modifications:

• the auxiliary membranes were CMX and AMX from Tokuyama Soda, Japan;

• the capillaries as well as the Ag/AgCI references electrodes (Metrohm type 6.0750.100) contained 3M KCI;

• the calibration liquid and the liquid in compartment 2, 3, 4 and 5 was 2.0 M NaCI solution at 25°C;

• the effective membrane area was 9.62 cm ² ;

• the distance between the capillaries was 5.0 mm;

• the measuring temperature was 25°C;

• a Cole Parmer Masterflex console drive (77521-47) with easy load II model 77200-62 gear pumps was used for all compartments; • the flowrate of each stream was 475 ml/min controlled by Porter Instrument flowmeters (type 150AV-B250-4RVS) and Cole Parmer flowmeters (type G- 30217-90); and

• the samples of anion exchange membrane were equilibrated for at least 1 hour at room temperature in a 0.5 M solution of NaCI prior to measurement.

The ER is preferably low, e.g. below 15 ohm. cm ² .

Table 1 : Ingredients

CL-1 was synthesized as described in US20160177006, Example 1 : General procedure for the preparation of AXL-1 to 4

To a 40% solution in PW of the corresponding amine (1 mmol) containing 4-OH- TEMPO (0.1 g), CMS-14 (2.02 mmol) were added dropwise for a 1 hour period. After that the mixture was stirred vigorously for 2 hours. Diethyl ether was added, and the Aqueous phase was extracted three times (3 x 200 ml_). The product was isolated from the water as a pale-yellow solid by spray drying.

Table 2: Structural elements of the AXL’s and the corresponding amines

Examples Ex1 to Ex6 and Comparable Examples CEx1 and CEx2.

Table 3: Curable Compositions and results

Table 3: Curable Compositions and results (continued)

The molar fraction of component (a) in Comparative Example 1 is low resulting in a low PS. In Comparative Example 2 component (a) is not according to Formula (I).

Preparation of The Curable Compositions and the Anion Exchange Membranes

The curable compositions shown in Table 3 above were prepared by mixing sequentially the stated amounts of the components (in wt%) in a mixture of the stated amounts of water/n-propanol at a temperature of 40°C.

Anion exchange membranes according to the first aspect of the present invention and Comparative Examples were prepared by applying at room temperature (21 °C) each of the curable compositions described in Table 3 to a porous support (PS1 ) using a 100|jm Meyer bar, removing excess curable composition using a 4pm Meyer bar and then curing the composition. UV curing was performed by placing the samples of the porous supports carrying the curable compositions on a conveyor at 5 m/min equipped with a D bulb in a Light Hammer® 10 of Fusion UV Systems Inc. and exposing the curable compositions to the UV light emitted from the D bulb at 50% power. The UV cured samples were covered by a 60pm polyethylene terephthalate (PET) foil without any surface treatment (from Toray) and were placed into a metallized vacuum sealed bag. The bag containing the UV cured membrane was then cured thermally (as a second curing step) in a regular oven for 3 hours at 90°C.